drugset / Trial / NCT02962063
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Phase 1/2
Active not recruiting
64 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of adding a new drug, durvalumab (also called MEDI4736), to chemoradiation with either FOLFOX/Capeox or carboplatin and paclitaxel, following initial chemotherapy with FOLFOX. The investigators want to find out what effects, good and/or bad, this combination has on the patient and cancer.
Timeline
- Start
- 2016-11
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Tremelimumab | Monoclonal antibody | 300 mg | — |
| Background | Carboplatin | Small molecule | 2 unknown | — |
| Background | Paclitaxel | Small molecule | 50 mg/m2 | — |